Major Depressive Disorder Clinical Trial
Official title:
Adjunct Total Sleep Deprivation, Sleep Phase Advance, and White Light Therapy Vs. Partial Sleep Deprivation, Sleep Phase Delay, and Amber Light Therapy as Adjunctive Treatments in Acutely Suicidal and Depressed Inpatients.
Chronotherapy is a term that describes therapeutic alterations of sleep wake cycles. Different variations of sleep deprivation, set sleep wake schedules, and types of light therapy have demonstrated efficacy in rapidly treating depression, and suicidal thinking. This study seeks to explore the effect of two different chronotherapuetic protocols on acutely depressed and suicidal inpatients admitted to the Medical University of South Carolina
There is a consistently reported, rapid antidepressant response to a single night of total
sleep deprivation in both unipolar, and bipolar depression. The clinical utility of this
technique has been limited however, because responders have typically relapsed rapidly
following recovery sleep. The addition of pharmacotherapy, sleep phase advance (a shift to an
earlier sleep schedule with normalization over three days), and bright light therapy to sleep
deprivation have each demonstrated efficacy in preventing relapse into depression. Combined
total sleep deprivation, sleep phase advance, and bright light therapy, dubbed Triple
Chronotherapy along with concomitant pharmacotherapy has demonstrated a rapid improvement in
depressive symptoms that has remained durable for as long as 9 weeks post intervention. If
the early, encouraging results of Triple Chronotherapy hold up to further study, the
technique represents a near ideal inpatient treatment, as it is inexpensive, relatively easy
to carry out, and has minimal side effects.
Despite encouraging early results, only one published report has attempted to use triple
chronotherapy in suicidal patients, and in that trial only bipolar depressed patients were
included, and one single variation of chronotherapy was tested (Three nights of sleep
deprivation every other night with three light therapy sessions, combined with lithium). The
lack of data in acutely suicidal patients significantly limits the utility of this
intervention in the United States, where few non-suicidal patients are admitted. Published
trials to this point have also excluded those with comorbid illness, which also limits the
clinical usefulness of this intervention to a minority of patients. Furthermore there are
sparse randomized adequately controlled trials, and still limited durability data on the
technique.
We recently explored the tolerability and feasibility of the technique on acutely depressed
and suicidal inpatients admitted to our inpatient unit with encouraging results. We
subsequently propose to further explore the utility of this technique by piloting its effect
compared to an active sham condition to determine if further study is indicated. Should
further study be warranted, we hope to use the collected pilot data to determine the
necessary number of participants to detect an effect.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |